- ISIN
- US74168J1016
- Sector
- Healthcare
- Industry
- Biotechnology
- IPO Date
- Oct 20, 2022
Highlights
- Market Cap
- $596.81M
- Enterprise Value
- $655.77M
- EPS (TTM)
- -$1.29
- Total Revenue (TTM)
- $3.18M
- Gross Profit (TTM)
- -$4.14M
- EBITDA (TTM)
- -$195.72M
- Year Range
- $2.18 - $6.94
- Target Price
- $17.25
- ROA (TTM)
- -67.31%
- ROE (TTM)
- -258.64%
Share Price Chart
Loading charts...
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Performance
PRME Performance Chart
Prime Medicine Inc. Common Stock (PRME) is down 2.9% since the beginning of the year. At $3 per share, PRME is trading 51.4% below its 52-week high of $7.
Loading charts...
Returns By Period
Prime Medicine Inc. Common Stock (PRME) has returned -2.88% so far this year and 62.80% over the past 12 months.
Prime Medicine Inc. Common Stock
- 1D
- 4.33%
- 1M
- 13.47%
- YTD
- -2.88%
- 6M
- -8.92%
- 1Y
- 62.80%
- 3Y*
- -39.21%
- 5Y*
- —
- 10Y*
- —
Benchmark (S&P 500 Index)
- 1D
- -0.37%
- 1M
- -0.01%
- YTD
- 9.16%
- 6M
- 8.64%
- 1Y
- 25.22%
- 3Y*
- 19.78%
- 5Y*
- 11.99%
- 10Y*
- 13.88%
PRME Monthly Returns History
Based on dividend-adjusted daily data since Oct 20, 2022, PRME's average daily return is -0.03%, while the average monthly return is -0.81%.
Historically, 38% of months were positive and 62% were negative. The best month was Jun 2025 with a return of +109.3%, while the worst month was Oct 2023 at -32.0%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 7 months.
On a daily basis, PRME closed higher 46% of trading days. The best single day was May 16, 2025 with a return of +26.2%, while the worst single day was Oct 20, 2022 at -19.0%.
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Total | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026 | 9.80% | 21.26% | -24.68% | 1.87% | 0.14% | -5.07% | -2.88% | ||||||
| 2025 | -4.11% | -10.00% | -21.03% | -13.07% | -31.79% | 109.32% | 51.42% | -13.37% | 70.99% | -10.83% | -22.67% | -9.16% | 18.84% |
| 2024 | -28.33% | 35.91% | -18.89% | -29.71% | 31.71% | -20.68% | 9.14% | -23.71% | -9.58% | 0.26% | -15.21% | -11.25% | -67.04% |
| 2023 | -5.38% | -6.54% | -25.14% | 11.95% | -0.36% | 6.78% | 2.87% | -12.14% | -27.95% | -31.97% | 11.86% | 22.04% | -52.31% |
| 2022 | -0.79% | -8.66% | 8.09% | -2.06% |
Benchmark Metrics
Prime Medicine Inc. Common Stock has an annualized alpha of -38.28%, beta of 2.00, and R2 of 0.12 versus S&P 500 Index. Calculated based on daily prices since October 20, 2022.
- This stock participated in 285.44% of S&P 500 Index downside but only 22.17% of its upside - more exposed to losses than it benefited from rallies.
- R2 of 0.12 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.
- Alpha
- -38.28%
- Beta
- 2.00
- R²
- 0.12
- Upside Capture
- 22.17%
- Downside Capture
- 285.44%
Return for Risk
Risk / Return Rank
PRME ranks 64 for risk / return — better than 64% of stocks on our site. You're getting solid returns for the risk taken. A good sign, especially for investors who want growth without excessive volatility.
Return / Risk — by metrics
The table below present risk-adjusted performance metrics for Prime Medicine Inc. Common Stock (PRME) and compare them to S&P 500 Index.
Values are calculated on a 1-year rolling basis and updated daily. Risk-adjusted metrics are more stable over longer periods — use the period switch above to explore them.
| PRME | Benchmark | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -1.37 | ||
| Sortino ratioReturn per unit of downside risk | -1.11 | ||
| Omega ratioGain probability vs. loss probability | 1.17 | 1.37 | -0.20 |
| Calmar ratioReturn relative to maximum drawdown | 1.06 | 2.78 | -1.72 |
| Martin ratioReturn relative to average drawdown | 1.66 | 12.44 | -10.78 |
Dividends
Dividend History
Drawdowns
Drawdowns Chart
The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.
Loading charts...
Worst Drawdowns
The table below displays the maximum drawdowns of the Prime Medicine Inc. Common Stock. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.
The maximum drawdown for the Prime Medicine Inc. Common Stock was 94.55%, occurring on Apr 8, 2025. The portfolio has not yet recovered.
The current Prime Medicine Inc. Common Stock drawdown is 84.04%.
Related event | Drawdown | Fall | Recovery | Underwater |
|---|---|---|---|---|
2025 selloff2025 | -94.55%Apr 2025 | 2y 4mo | — | 3y 7moNov 2022 - now |
Bear market2022 | -19.87%Oct 2022 | 4d | 8d | 12dOct 2022 - Nov 2022 |
Bear market2022 | -14.06%Nov 2022 | 5d | 4d | 9dNov 2022 - Nov 2022 |
Drawdown Indicators
| PRME | Benchmark | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -94.55% | -56.78% | -37.77% |
Max Drawdown (1Y)Largest decline over 1 year | -59.52% | -9.10% | -50.42% |
Max Drawdown (3Y)Largest decline over 3 years | -92.37% | -18.90% | -73.47% |
Max Drawdown (5Y)Largest decline over 5 years | — | -25.43% | — |
Max Drawdown (10Y)Largest decline over 10 years | — | -33.92% | — |
Current DrawdownCurrent decline from peak | -84.04% | -1.80% | -82.24% |
Average DrawdownAverage peak-to-trough decline | -65.61% | -10.71% | -54.90% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 38.02% | 2.03% | +35.99% |
Volatility
Volatility Chart
The chart below shows the rolling one-month volatility.
Loading charts...
Financials
Financial Performance
The chart below illustrates the trends in the financial health of Prime Medicine Inc. Common Stock over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.
Valuation
The Valuation section provides an overview of how Prime Medicine Inc. Common Stock is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.
PS Ratio
This chart shows the Price-to-Sales (P/S) ratio for PRME relative to other companies in the Biotechnology industry. Currently, PRME has a P/S ratio of 163.2. This P/S ratio is high relative to other companies in the industry. It could mean the stock is overvalued, or that investors expect strong future growth and profitability.
PB Ratio
The chart illustrates the Price-to-Book (P/B) ratio for PRME in comparison with other companies in the Biotechnology industry. Currently, PRME has a P/B value of 7.8. This P/B ratio is higher than most companies in the industry. It may suggest the stock is overvalued or that investors expect the company to generate high returns on its assets.
Income Statement
| TTM | |
|---|---|
Revenue | — |
Total Revenue | — |
Cost Of Revenue | — |
Gross Profit | — |
Operating Expenses | — |
Selling, General & Admin Expenses | — |
R&D Expenses | — |
Depreciation And Amortization | — |
Total Operating Expenses | — |
Income | — |
Income Before Tax | — |
Operating Income | — |
EBITDA | — |
EBIT | — |
Earnings From Continuing Operations | — |
Net Income | — |
Income Tax Expense | — |
Other Non-Operating Income (Expenses) | — |
Extraordinary Items | — |
Discontinued Operations | — |
Effect Of Accounting Charges | — |
Non Recurring | — |
Minority Interest | — |
Other Items | — |
Interest Income | — |
Interest Expense | — |
Net Interest Income | — |
Build a portfolio with PRME
Add Prime Medicine Inc. Common Stock to a portfolio and analyze allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Analyzer with PRME